Abstract
Mice were intragastrically treated with single doses (0.05-0.8 g/kg) of schisandrin B (a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis). Twenty-four hours after schisandrin B administration, the serum triglyceride level was increased by 10-235% in a dose-dependent manner. However, the serum low density lipoprotein cholesterol level was significantly decreased by 28% at a dose of 0.8 g/kg. When given once daily (0.01-0.2 g/kg) for 4 days, schisandrin B also dose-dependently elevated the serum triglyceride level (17-134%). Kinetics parameters estimated by Scott's plot analysis of schisandrin B-induced changes in serum and hepatic triglyceride levels were determined: serum-E(max) (maximal effect)=6 mmol/L (384% increase, P<0.001); K(D) (affinity)=0.59 mmol/kg; pD(2) (an index of affinity)=6.62; liver-E(max)=21 micromol/g (68% increase, P<0.001); K(D)=0.37 mmol/kg; pD(2)=6.83. The efficacy of schisandrin B in increasing the triglyceride level was 5.6-fold higher in serum than in liver tissue. Fenofibrate (0.2g/kg) treatment, when in combination with schisandrin B (0.2g/kg), for 4 days significantly reduced the schisandrin B-induced increase in serum triglyceride level (by 81%, P<0.001). Hepatic tr...Continue Reading
References
Oct 1, 1995·Planta medica·S P IpK M Ko
Dec 1, 1995·The Journal of Clinical Investigation·P H WeinstockJ L Breslow
Apr 1, 1996·Journal of Cardiovascular Risk·J E Hokanson, M A Austin
Jan 17, 1997·Science·L Masucci-MagoulasA R Tall
Nov 14, 1997·European Journal of Clinical Investigation·S EatonK Bartlett
May 6, 1998·Atherosclerosis·M H HofkerL M Havekes
Mar 27, 2002·Planta medica·S Y PanK M Ko
Jul 16, 2003·Atherosclerosis·K L KhooE Janus
Aug 6, 2003·Free Radical Biology & Medicine·Po Yee ChiuKam Ming Ko
Dec 3, 2003·Atherosclerosis·Patricia BlackburnJean Pierre Després
Jan 8, 2004·Physiological Genomics·Takahiro UenoPavel Hamet
Feb 6, 2004·BioFactors·Man Ho TangKam Ming Ko
Sep 29, 2004·Pharmacology·S Y Pan, Y F Han
Jan 11, 2005·Current Vascular Pharmacology·Vasilis TsimihodimosMoses S Elisaf
Citations
Apr 28, 2011·Naunyn-Schmiedeberg's Archives of Pharmacology·Si-Yuan PanKam-Ming Ko
Oct 11, 2011·Natural Product Research·Xiaoqiang ChenLei Yang
Jul 14, 2009·Evidence-based Complementary and Alternative Medicine : ECAM·Si-Yuan PanKam-Ming Ko
Jul 26, 2011·Evidence-based Complementary and Alternative Medicine : ECAM·Si-Yuan PanKam-Ming Ko
Aug 1, 2012·PloS One·Zhen LiuXun Hu
Mar 14, 2014·Lipids in Health and Disease·Nan SunKam-Ming Ko
Oct 19, 2006·European Journal of Pharmacology·Si-Yuan PanKam-Ming Ko
Jan 25, 2011·Journal of Ethnopharmacology·Eun Young KimMee Ra Rhyu
Oct 8, 2013·Journal of Pharmacological Sciences·Si-Yuan PanKam-Ming Ko
May 2, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Si-Yuan PanKam-Ming Ko
Mar 15, 2015·Scientific Reports·Hiu Yee KwanZhi-Ling Yu
Feb 21, 2008·The Journal of Pharmacy and Pharmacology·Si-Yuan PanKam-Ming Ko
Dec 7, 2007·The Journal of Pharmacy and Pharmacology·Si-Yuan PanKam-Ming Ko
Nov 18, 2016·Lipids in Health and Disease·Chun-Mei WangJian-Guang Chen
Jan 15, 2017·Lipids in Health and Disease·Yi ZhangKam-Ming Ko
Jan 23, 2013·Journal of Proteome Research·Hiu Yee KwanWang Fun Fong